Scott Wolfe advises start-up and emerging businesses and public companies, particularly in the life sciences and high-technology industries. He regularly represents companies and investment banking firms in public offerings, private placements, venture capital financings, real estate investment trusts, debt offerings, corporate partnering arrangements, and mergers and acquisitions.
Mr. Wolfe is a member of the American, California and San Diego Bar Associations. He is the former Chairman and current trustee and member of the Executive Committee of Rady Children's Hospital and Health Center in San Diego. He is a trustee of BIOCOM, CONNECT and the Corporate Directors Forum, Counsel for the Sanford Consortium of Regenerative Medicine and member of the Dean's Advisory Council of the Rady School of Management at UCSD and lecturer on venture capital and mergers and acquisitions. Mr. Wolfe is a former owner of the San Diego Padres (1990–1999). He is an Xconomist for Xconomy, the online technology newspaper and serves as a board member of the Corporate Directors Forum. In 2012, he was a panelist at the West Coast Board Summit and Peer Exchange sponsored by NYSE Euronext and Corporate Board Member. He is an Adjunct Professor of Law at USD Law School teaching a class in “Advanced Corporate Transactional Skills.”
Mr. Wolfe has been selected for inclusion in Best Lawyers in America (1991–2013), recommended as a Leading Lawyer by Chambers USA 2013 for his work in Life Science as well as Capital Markets: Debt & Equity. In 2013, Mr. Wolfe was named the San Diego "Lawyer of the Year" in Corporate Law, an honor that is awarded to only one lawyer per practice area in the nation’s largest legal markets and is based upon the recommendations of his peers and was the recipient of the 2013 Thomas F. Carter Award, the highest leadership and philanthropic award given by Rady Children’s Hospital and Health Center – San Diego. Mr. Wolfe was named the San Diego Venture Capital Lawyer of the Year for 2012 and The Legal 500 US lists him as one of the “important M&A practitioners.” In 2006, Mr. Wolfe was selected as one of San Diego’s 120 Top Influentials by the Daily Transcript in its special 120th anniversary “Past to Present” issue, a feature of the most influential business leaders in San Diego from 1886 to 2006. In 2004, Mr. Wolfe tied for second as the US lawyer with the most IPO representations as cited by IPO Vital Signs.
Mr. Wolfe's experience includes representation of:
- Cubic Corporation, a public defense and transportation company in connection with a US$100 million secondary offering and general securities and corporate governance advice
- DJO Global, a medical device company, in connection with public offerings aggregating US$250 million, its US$1.6 billion acquisition by The Blackstone Group and follow-on acquisitions of Dr. Comfort and Elastic Therapy of US$300 million
- Goldman Sachs and Lehman Brothers as co-lead underwriters of Qualcomm's IPO
- Ligand Pharmaceuticals, Inc., a public biotechnology company, in connection with the sale of its Avinza pain product and its oncology products for more than US$500 million
- Morgan Stanley as lead underwriter of Foodmaker Inc. (Jack in the Box)'s IPO
- NTI Group, an e-mail and text messaging company in the educational sector, in connection with its US$200 million merger with Blackboard, Inc.
- Orchid Pharmaceuticals, a pharmaceutical company in India, in connection with its US$400 million sale of a facility and anti-infective business in India to Hospira, Inc.
- Pirch, Inc., a retailer of kitchen, bath and outdoor living products, in connection with an investment by private equity firm Catterton Partners
- PriceClub in connection with its merger with Costco and the spin-off of Price Enterprises and PriceSmart
- San Diego Padres Baseball Club in connection with its acquisition and later the sale of a majority interest and as general counsel from 1990-1994
- Santarus, Inc. a specialty pharmaceuticals company, in connection with its IPO and a follow-on offering valued at over US$130 million, with general securities, acquisition and corporate governance advice, and with the sale of Santarus to Salix Pharmaceuticals for US$2.6 billion
- SkinMedica, Inc., a specialty pharmaceutical company focused on dermatology, in venture capital financings valued at approximately US$115 million, the sale of pharmaceutical products to Bayer, its acquisition of Colorescience and its sale to Allergan for US$375 million